Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

NCT07089719 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT07089719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07089719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
May 1, 2028
Enrollment
21 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dyspnea caused by 2019-ncov